Novartis price target raised to $104 from $93 at Leerink Leerink raised its price target for Novartis shares to $104 on expectations the company's LCZ696 should be able to replace angiotensin converting enzyme inhibitors / angiotensin receptor blockers therapies over time. It keeps an Outperform rating on the stock.
News For NVS From The Last 14 Days
Check below for free stories on NVS the last two weeks.
Novartis treatment for pigmented villonodular synovitis gets orphan designation According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link